Abstract
Interest in the effectiveness of psychological interventions in patients with psychosis has increased in the last 2 decades, and early intervention programs are increasingly common. PIENSA (Programa de Intervención en Psicosis Adolescente; Intervention Program for Adolescent Psychosis) is a clinical program and pilot study based on previous research into the efficacy of early intervention in preventing relapse and improving outcome in patients with first-episode psychosis.
We describe a psychoeducational intervention designed for adolescents with early-onset psychosis and their parents. The intervention is adapted from McFarlane’s Multiple Family Therapy model to our setting and population (adolescents treated in the Spanish public health system). It consists of 2 stages: an individual stage comprising 3 sessions and a subsequent group stage comprising 12 sessions. The total program lasts for 1 academic year (9 months).
We present the design of our program and our preliminary experience in a Child and Adolescent Unit in Spain.
Keywords: Adolescents, family intervention, group therapy, psychoeducational, psychosis, treatment.
Adolescent Psychiatry
Title:PIENSA: Development of an Early Intervention Program for Adolescents With Early-Onset Psychosis and Their Families
Volume: 2 Issue: 3
Author(s): Ana Ruiz-Sancho, Ana Calvo, Marta Rapado-Castro, Miguel Moreno, Carmen Moreno, Teresa Sanchez-Gutierrez, Cecilia Tapia, Guadalupe Chiclana, Pamela Rodriguez, Patricia Fernandez, Celso Arango and Maria Mayoral
Affiliation:
Keywords: Adolescents, family intervention, group therapy, psychoeducational, psychosis, treatment.
Abstract: Interest in the effectiveness of psychological interventions in patients with psychosis has increased in the last 2 decades, and early intervention programs are increasingly common. PIENSA (Programa de Intervención en Psicosis Adolescente; Intervention Program for Adolescent Psychosis) is a clinical program and pilot study based on previous research into the efficacy of early intervention in preventing relapse and improving outcome in patients with first-episode psychosis.
We describe a psychoeducational intervention designed for adolescents with early-onset psychosis and their parents. The intervention is adapted from McFarlane’s Multiple Family Therapy model to our setting and population (adolescents treated in the Spanish public health system). It consists of 2 stages: an individual stage comprising 3 sessions and a subsequent group stage comprising 12 sessions. The total program lasts for 1 academic year (9 months).
We present the design of our program and our preliminary experience in a Child and Adolescent Unit in Spain.
Export Options
About this article
Cite this article as:
Ruiz-Sancho Ana, Calvo Ana, Rapado-Castro Marta, Moreno Miguel, Moreno Carmen, Sanchez-Gutierrez Teresa, Tapia Cecilia, Chiclana Guadalupe, Rodriguez Pamela, Fernandez Patricia, Arango Celso and Mayoral Maria, PIENSA: Development of an Early Intervention Program for Adolescents With Early-Onset Psychosis and Their Families, Adolescent Psychiatry 2012; 2 (3) . https://dx.doi.org/10.2174/2210676611202030229
DOI https://dx.doi.org/10.2174/2210676611202030229 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Structure-Based β-Secretase (BACE1) Inhibitors
Current Pharmaceutical Design Triazene Compounds in the Treatment of Acute Myeloid Leukemia: A Short Review and a Case Report
Current Medicinal Chemistry Application of Nanobioinformatics in Medical Science – A Probable Therapy
Current Bioinformatics Iron Leads to Memory Impairment that is Associated with a Decrease in Acetylcholinesterase Pathways
Current Neurovascular Research Neuroimaging of Narcolepsy
CNS & Neurological Disorders - Drug Targets Indoles - Gut Bacteria Metabolites of Tryptophan with Pharmacotherapeutic Potential
Current Drug Metabolism Neuromodulation of the Perinatal Respiratory Network
Current Neuropharmacology Applications of Nanotechnology in Diagnostics and Therapeutics of Alzheimer’s and Parkinson’s Disease
Current Drug Metabolism Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions
Current Alzheimer Research The Early Involvement of the Innate Immunity in the Pathogenesis of Lateonset Alzheimers Disease: Neuropathological, Epidemiological and Genetic Evidence
Current Alzheimer Research Inflammasome in Dendritic Cells Immunobiology: Implications to Diseases and Therapeutic Strategies
Current Drug Targets Prognostic and Predictive Molecular Markers in Cutaneous Malignant Melanoma: The First Step Toward Personalized Medicine
Current Pharmacogenomics and Personalized Medicine A Mechanistic Study on Altered Pharmacokinetics of Irinotecan by St. Johns Wort
Current Drug Metabolism Dystonia Associated with Lamotrigine Therapy: A Case Report and Review of the Literature
Current Drug Safety Amyloid β-induced Mesenteric Inflammation in an Alzheimer’s Disease Transgenic Mouse Model
Current Alzheimer Research New Therapeutic Strategies for Coeliac Disease: Tissue Transglutaminase as a Target
Current Medicinal Chemistry Deleted in Colorectal Cancer (DCC) Pathfinding: Axon Guidance Gene Finally Turned Tumor Suppressor
Current Drug Targets Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Structural Preferences of Neuroprotective S14G-Humanin Peptide Analyzed by Molecular Modeling and Circular Dichroism
Protein & Peptide Letters Metabotropic GABAB Receptors New Challenges in Drug Design
Current Medicinal Chemistry - Central Nervous System Agents